# US 2026/0098099 A1 · Anti-soluble interleukin-7 receptor antibody therapy to treat autoimmune diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0098099 A1
- Document ID: US20260098099A1
- Status: Published application
- Kind: A1
- Application number: 19/295,663
- Filed: 2025-08-10
- Published: 2026-04-09
- Earliest claimed: 2022-04-13
- Assignees: Board of Regents, The University of Texas System; Autoimmunity Biologic Solutions, Inc.
- Applicants: Board of Regents, the University of Texas System; Autoimmunity Biologic Solutions, Inc.
- Inventors: Mariano A. GARCIA-BLANCO; Gaddiel GALARZA-MUNOZ
- Web page: https://patentgrep.com/patent/US20260098099A1

## CPC

- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61P 37/02: Immunomodulators
- A61K 2039/505: {comprising antibodies}
- C07K 2317/31: multispecific
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Recent studies indicate that sIL7R is involved in the development of autoimmune diseases. The present invention provides methods and compositions for a novel antibody therapeutic against the soluble isoform of the interleukin 7 receptor (sIL7R), a potent driver of self-destructive immune responses that cause autoimmune diseases including multiple sclerosis, lupus nephritis, type I diabetes, rheumatoid arthritis, systemic lupus erythematosus, and many other autoimmune diseases. The present invention includes antibodies specific for sIL7R that inhibit SIL7R, a driver of autoimmunity, without inhibiting mIL7R, thereby reducing the severity of or preventing autoimmunity without activating immunosuppressive mechanisms.

## Claims

### Claim 1

A pharmaceutical composition comprising anti-sIL7R antibodies that bind to and neutralize sIL7R (soluble isoform of the interleukin 7 receptor) or reduce sIL7R from circulation without inhibiting the alpha chain of the interleukin 7 receptor (mIL7R).

### Claim 2 (depends on 1)

A method of treating an autoimmune disease comprising administering a therapeutic amount of the pharmaceutical composition of claim 1.

### Claim 3 (depends on 2)

The method of claim 2, wherein the autoimmune disease is one or more of achalasia, Addison's disease, adult Still's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM/anti-TBM nephritis, antiphospholipid syndrome, atopic dermatitis, autoimmune angioedema, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune urticaria, axonal & neuronal neuropathy (AMAN), Baló disease, Behcet's disease, benign mucosal pemphigoid, bullous pemphigoid, Castleman disease (CD), celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss syndrome (CSS) or eosinophilic granulomatosis (EGPA), cicatricial pemphigoid, Cogan's syndrome, cold agglutinin disease, congenital heart block, Coxsackie myocarditis, CREST syndrome, Crohn's disease, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressler's syndrome, endometriosis, eosinophilic esophagitis (EoE), eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, Evans syndrome, Fibromyalgia, Fibrosing alveolitis, Giant cell arteritis (temporal arteritis), Giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis, Graves' disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura (HSP), herpes gestationis or pemphigoid gestationis (PG), hidradenitis suppurativa (HS) (acne inversa), hypogammalglobulinemia, IgA nephropathy (IgAN), IgG4-related sclerosing disease, Immune thrombocytopenia purpura (ITP), Inclusion body myositis (IBM), Interstitial cystitis (IC), juvenile arthritis, juvenile diabetes (type 1 diabetes), juvenile myositis (JM), Kawasaki disease, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), lupus, lupus nephritis, lyme disease chronic, Meniere's disease, microscopic polyangiitis (MPA), mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, multifocal motor neuropathy (MMN) or MMNCB, multiple sclerosis (all forms of multiple sclerosis, including progression independent of relapse activity (PIRA), relapse-associated worsening (RAW), relapsing forms, and progressive forms), myasthenia gravis, myelin oligodendrocyte glycoprotein antibody disorder, myositis, narcolepsy, neonatal lupus, neuromyelitis optica, neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism (PR), PANDAS, paraneoplastic cerebellar degeneration (PCD), paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, pars planitis (peripheral uveitis), Parsonage-Turner syndrome, pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia (PA), POEMS syndrome, polyarteritis nodosa, polyglandular syndromes type I, II, III, polymyalgia rheumatica, polymyositis, postmyocardial infarction syndrome, postpericardiotomy syndrome, primary biliary cholangitis, primary sclerosing cholangitis, primary Sjögren's syndrome, progesterone dermatitis, psoriasis, psoriatic arthritis, pure red cell aplasia (PRCA), pyoderma gangrenosum, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome (RLS), retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjögren's syndrome, sperm & testicular autoimmunity, stiff person syndrome (SPS), subacute bacterial endocarditis (SBE), Susac's syndrome, sympathetic ophthalmia (SO), systemic lupus erythematosus (SLE), Takayasu's arteritis, temporal arteritis/giant cell arteritis, thrombocytopenia purpura (TTP), thyroid eye disease (TED), Tolosa-Hunt syndrome (THS), transverse myelitis, type 1 diabetes, ulcerative colitis (UC), undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vitiligo, Vogt-Koyanagi-Harada disease, primary biliary cirrhosis and inflammatory bowel syndrome.

### Claim 4 (depends on 2)

The method of claim 2, wherein the anti-sIL7R antibodies are administered intravenously, subcutaneously, intradermally, topically, intranasally, intraperitoneally, intraocularly, orally, rectally, intrathecally, intraventricularly, vaginally, intramuscularly or directly into the central nervous system (CNS).

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the anti-sIL7R antibodies target one or more regions of sIL7R that are different from mIL7R.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the anti-sIL7R antibodies are antibody fragments, binding proteins, fusion proteins or synthetic proteins.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is formulated for sustained release or extended release.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, wherein the anti-sIL7R antibody is comprised of a heavy chain selected from SEQ ID NO: 105, 111, 115, 119, 123, 127, 131, 135, 137, 141, 145 and 149; and a light chain selected from SEQ ID NO: 107, 109, 113, 117, 121, 125, 129, 133, 139, 143, 147 and 151.

### Claim 9 (depends on 8)

The pharmaceutical composition of claim 8, wherein the anti-sIL7R antibodies comprise one or more conservative amino acid substitutions.

### Claim 10

An antibody which binds to sIL7R, the antibody selected from:
(a) an antibody comprising a heavy chain variable region comprising heavy chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 152, heavy chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 153, and heavy chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 154, and a light chain variable region comprising light chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 155, light chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 156, and light chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 157;
(b) an antibody comprising a heavy chain variable region comprising heavy chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 158, heavy chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 159, and heavy chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 160, and a light chain variable region comprising light chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 161, light chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 162, and light chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 163;
(c) an antibody comprising a heavy chain variable region comprising heavy chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 164, heavy chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 165, and heavy chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 166, and a light chain variable region comprising light chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 167, light chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 168, and light chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 169;
(d) an antibody comprising a heavy chain variable region comprising heavy chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 170, heavy chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 171, and heavy chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 172, and a light chain variable region comprising light chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 173, light chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 174, and light chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 175;
(e) an antibody comprising a heavy chain variable region comprising heavy chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 176, heavy chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 177, and heavy chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 178, and a light chain variable region comprising light chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 179, light chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 180, and light chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 181;
(f) an antibody comprising a heavy chain variable region comprising heavy chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 182, heavy chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 183, and heavy chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 184, and a light chain variable region comprising light chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 185, light chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 186, and light chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 187;
(g) an antibody comprising a heavy chain variable region comprising heavy chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 188, heavy chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 189, and heavy chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 190, and a light chain variable region comprising light chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 191, light chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 192, and light chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 193;
(h) an antibody comprising a heavy chain variable region comprising heavy chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 194, heavy chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 195, and heavy chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 196, and a light chain variable region comprising light chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 197, light chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 198, and light chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 199;
(i) an antibody comprising a heavy chain variable region comprising heavy chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 200, heavy chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 201, and heavy chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 202, and a light chain variable region comprising light chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 203, light chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 204, and light chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 205;
(j) an antibody comprising a heavy chain variable region comprising heavy chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 206, heavy chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 207, and heavy chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 208, and a light chain variable region comprising light chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 209, light chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 210, and light chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 211;
(k) an antibody comprising a heavy chain variable region comprising heavy chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 212, heavy chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 213, and heavy chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 214, and a light chain variable region comprising light chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 215, light chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 216, and light chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 217;
(l) an antibody comprising a heavy chain variable region comprising heavy chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 218, heavy chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 219, and heavy chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 220, and a light chain variable region comprising light chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 221, light chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 222, and light chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 223; and
(m) an antibody comprising a heavy chain variable region comprising heavy chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 224, heavy chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 225, and heavy chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 226, and a light chain variable region comprising light chain CDR1 containing at least the amino acid sequence as set forth in SEQ ID NO: 227, light chain CDR2 containing at least the amino acid sequence as set forth in SEQ ID NO: 228, and light chain CDR3 containing at least the amino acid sequence as set forth in SEQ ID NO: 229.

### Claim 11 (depends on 10)

The antibody of claim 10, wherein the antibody does not bind to mIL7R.

### Claim 12 (depends on 10)

The antibody of claim 10, wherein the antibody binds to one of the sIL7R-specific C-terminal tail (encoded by exon 7 in transcripts that skip exon 6), and/or the region of sIL7R encoded by the junction between exons 5 and 7 in transcripts that skip exon 6.

### Claim 13 (depends on 10)

A method of treating an ailment, the method comprising administering a composition comprising the antibody of claim 10.

### Claim 14 (depends on 13)

The method of claim 13, wherein the ailment is an autoimmune disease.

### Claim 15 (depends on 14)

The method of claim 14, wherein the autoimmune disease is one or more of achalasia, Addison's disease, adult Still's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM/anti-TBM nephritis, antiphospholipid syndrome, atopic dermatitis, autoimmune angioedema, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune urticaria, axonal & neuronal neuropathy (AMAN), Baló disease, Behcet's disease, benign mucosal pemphigoid, bullous pemphigoid, Castleman disease (CD), celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss syndrome (CSS) or eosinophilic granulomatosis (EGPA), cicatricial pemphigoid, Cogan's syndrome, cold agglutinin disease, congenital heart block, Coxsackie myocarditis, CREST syndrome, Crohn's disease, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressler's syndrome, endometriosis, eosinophilic esophagitis (EoE), eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, Evans syndrome, Fibromyalgia, Fibrosing alveolitis, Giant cell arteritis (temporal arteritis), Giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis, Graves' disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura (HSP), herpes gestationis or pemphigoid gestationis (PG), hidradenitis suppurativa (HS) (acne inversa), hypogammalglobulinemia, IgA nephropathy (IgAN), IgG4-related sclerosing disease, Immune thrombocytopenia purpura (ITP), Inclusion body myositis (IBM), Interstitial cystitis (IC), juvenile arthritis, juvenile diabetes (type 1 diabetes), juvenile myositis (JM), Kawasaki disease, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), lupus, lupus nephritis, lyme disease chronic, Meniere's disease, microscopic polyangiitis (MPA), mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, multifocal motor neuropathy (MMN) or MMNCB, multiple sclerosis (all forms of multiple sclerosis, including progression independent of relapse activity (PIRA), relapse-associated worsening (RAW), relapsing forms, and progressive forms), myasthenia gravis, myelin oligodendrocyte glycoprotein antibody disorder, myositis, narcolepsy, neonatal lupus, neuromyelitis optica, neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism (PR), PANDAS, paraneoplastic cerebellar degeneration (PCD), paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, pars planitis (peripheral uveitis), Parsonage-Turner syndrome, pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia (PA), POEMS syndrome, polyarteritis nodosa, polyglandular syndromes type I, II, III, polymyalgia rheumatica, polymyositis, postmyocardial infarction syndrome, postpericardiotomy syndrome, primary biliary cholangitis, primary sclerosing cholangitis, primary Sjögren's syndrome, progesterone dermatitis, psoriasis, psoriatic arthritis, pure red cell aplasia (PRCA), pyoderma gangrenosum, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome (RLS), retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjögren's syndrome, sperm & testicular autoimmunity, stiff person syndrome (SPS), subacute bacterial endocarditis (SBE), Susac's syndrome, sympathetic ophthalmia (SO), systemic lupus erythematosus (SLE), Takayasu's arteritis, temporal arteritis/giant cell arteritis, thrombocytopenia purpura (TTP), thyroid eye disease (TED), Tolosa-Hunt syndrome (THS), transverse myelitis, type 1 diabetes, ulcerative colitis (UC), undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vitiligo, Vogt-Koyanagi-Harada disease, primary biliary cirrhosis and inflammatory bowel syndrome.

### Claim 16 (depends on 13)

The method of claim 13, wherein the method does not suppress the immune system below normal activity.

### Claim 17 (depends on 13)

The method of claim 13, further comprising administering one or more additional medicaments to treat the autoimmune disease.

### Claim 18 (depends on 13)

The method of claim 13, wherein the method reduces the activity of sIL7R by neutralizing the activity of sIL7R and/or reducing the levels of circulating sIL7R without inhibiting mIL7R.

### Claim 19 (depends on 13)

The method of claim 13, wherein the composition is administered with a second therapeutic agent, the second therapeutic agent selected from an immunomodulatory agent, a small molecule or a biologic.

### Claim 20

A method of treating an autoimmune disease in a subject without suppressing the immune system below normal activity, the method comprising neutralizing and/or reducing the amount of sIL7R in the subject.

### Claim 21 (depends on 19)

The method of claim 19, wherein the method comprises administering an anti-sIL7R antibody or anti-sIL7R antagonist to the subject.

### Claim 22 (depends on 19)

The method of claim 19, wherein the autoimmune disease is one or more of achalasia, Addison's disease, adult Still's disease, agammaglobulinemia, alopecia areata, amyloidosis, ankylosing spondylitis, anti-GBM/anti-TBM nephritis, antiphospholipid syndrome, atopic dermatitis, autoimmune angioedema, autoimmune dysautonomia, autoimmune encephalomyelitis, autoimmune hepatitis, autoimmune inner ear disease (AIED), autoimmune myocarditis, autoimmune oophoritis, autoimmune orchitis, autoimmune pancreatitis, autoimmune retinopathy, autoimmune urticaria, axonal & neuronal neuropathy (AMAN), Baló disease, Behcet's disease, benign mucosal pemphigoid, bullous pemphigoid, Castleman disease (CD), celiac disease, Chagas disease, chronic inflammatory demyelinating polyneuropathy (CIDP), chronic recurrent multifocal osteomyelitis (CRMO), Churg-Strauss syndrome (CSS) or eosinophilic granulomatosis (EGPA), cicatricial pemphigoid, Cogan's syndrome, cold agglutinin disease, congenital heart block, Coxsackie myocarditis, CREST syndrome, Crohn's disease, dermatitis herpetiformis, dermatomyositis, Devic's disease (neuromyelitis optica), discoid lupus, Dressler's syndrome, endometriosis, eosinophilic esophagitis (EoE), eosinophilic fasciitis, erythema nodosum, essential mixed cryoglobulinemia, Evans syndrome, Fibromyalgia, Fibrosing alveolitis, Giant cell arteritis (temporal arteritis), Giant cell myocarditis, glomerulonephritis, Goodpasture's syndrome, granulomatosis with polyangiitis, Graves' disease, Guillain-Barre syndrome, Hashimoto's thyroiditis, hemolytic anemia, Henoch-Schonlein purpura (HSP), herpes gestationis or pemphigoid gestationis (PG), hidradenitis suppurativa (HS) (acne inversa), hypogammalglobulinemia, IgA nephropathy (IgAN), IgG4-related sclerosing disease, Immune thrombocytopenia purpura (ITP), Inclusion body myositis (IBM), Interstitial cystitis (IC), juvenile arthritis, juvenile diabetes (type 1 diabetes), juvenile myositis (JM), Kawasaki disease, Lambert-Eaton syndrome, leukocytoclastic vasculitis, lichen planus, lichen sclerosus, ligneous conjunctivitis, linear IgA disease (LAD), lupus, lupus nephritis, lyme disease chronic, Meniere's disease, microscopic polyangiitis (MPA), mixed connective tissue disease (MCTD), Mooren's ulcer, Mucha-Habermann disease, multifocal motor neuropathy (MMN) or MMNCB, multiple sclerosis (all forms of multiple sclerosis, including progression independent of relapse activity (PIRA), relapse-associated worsening (RAW), relapsing forms, and progressive forms), myasthenia gravis, myelin oligodendrocyte glycoprotein antibody disorder, myositis, narcolepsy, neonatal lupus, neuromyelitis optica, neutropenia, ocular cicatricial pemphigoid, optic neuritis, palindromic rheumatism (PR), PANDAS, paraneoplastic cerebellar degeneration (PCD), paroxysmal nocturnal hemoglobinuria (PNH), Parry Romberg syndrome, pars planitis (peripheral uveitis), Parsonage-Turner syndrome, pemphigus, peripheral neuropathy, perivenous encephalomyelitis, pernicious anemia (PA), POEMS syndrome, polyarteritis nodosa, polyglandular syndromes type I, II, III, polymyalgia rheumatica, polymyositis, postmyocardial infarction syndrome, postpericardiotomy syndrome, primary biliary cholangitis, primary sclerosing cholangitis, primary Sjögren's syndrome, progesterone dermatitis, psoriasis, psoriatic arthritis, pure red cell aplasia (PRCA), pyoderma gangrenosum, Raynaud's phenomenon, reactive arthritis, reflex sympathetic dystrophy, relapsing polychondritis, restless legs syndrome (RLS), retroperitoneal fibrosis, rheumatic fever, rheumatoid arthritis, sarcoidosis, Schmidt syndrome, scleritis, scleroderma, Sjögren's syndrome, sperm & testicular autoimmunity, stiff person syndrome (SPS), subacute bacterial endocarditis (SBE), Susac's syndrome, sympathetic ophthalmia (SO), systemic lupus erythematosus (SLE), Takayasu's arteritis, temporal arteritis/giant cell arteritis, thrombocytopenia purpura (TTP), thyroid eye disease (TED), Tolosa-Hunt syndrome (THS), transverse myelitis, type 1 diabetes, ulcerative colitis (UC), undifferentiated connective tissue disease (UCTD), uveitis, vasculitis, vitiligo, Vogt-Koyanagi-Harada disease, primary biliary cirrhosis and inflammatory bowel syndrome.

### Claim 23 (depends on 19)

The method of claim 19, wherein the method comprises administering a therapeutic amount of an antibody selected from:
(a) an antibody comprising a heavy chain containing at least the amino acid sequence as set forth in SEQ ID NO: 105, and light chain containing at least the amino acid sequence as set forth in SEQ ID NO: 107;
(b) an antibody comprising a heavy chain containing at least the amino acid sequence as set forth in SEQ ID NO: 105, and light chain containing at least the amino acid sequence as set forth in SEQ ID NO: 109;
(c) an antibody comprising a heavy chain containing at least the amino acid sequence as set forth in SEQ ID NO: 111, and light chain containing at least the amino acid sequence as set forth in SEQ ID NO: 113;
(d) an antibody comprising a heavy chain containing at least the amino acid sequence as set forth in SEQ ID NO: 115, and light chain containing at least the amino acid sequence as set forth in SEQ ID NO: 117;
(e) an antibody comprising a heavy chain containing at least the amino acid sequence as set forth in SEQ ID NO: 119, and light chain containing at least the amino acid sequence as set forth in SEQ ID NO: 121;
(f) an antibody comprising a heavy chain containing at least the amino acid sequence as set forth in SEQ ID NO: 123, and light chain containing at least the amino acid sequence as set forth in SEQ ID NO: 125;
(g) an antibody comprising a heavy chain containing at least the amino acid sequence as set forth in SEQ ID NO: 127, and light chain containing at least the amino acid sequence as set forth in SEQ ID NO: 129;
(h) an antibody comprising a heavy chain containing at least the amino acid sequence as set forth in SEQ ID NO: 131, and light chain containing at least the amino acid sequence as set forth in SEQ ID NO: 133;
(i) an antibody comprising a heavy chain containing at least the amino acid sequence as set forth in SEQ ID NO: 135, and light chain containing at least the amino acid sequence as set forth in SEQ ID NO: 139;
(j) an antibody comprising a heavy chain containing at least the amino acid sequence as set forth in SEQ ID NO: 137, and light chain containing at least the amino acid sequence as set forth in SEQ ID NO: 139;
(k) an antibody comprising a heavy chain containing at least the amino acid sequence as set forth in SEQ ID NO: 141, and light chain containing at least the amino acid sequence as set forth in SEQ ID NO: 143;
(l) an antibody comprising a heavy chain containing at least the amino acid sequence as set forth in SEQ ID NO: 145, and light chain containing at least the amino acid sequence as set forth in SEQ ID NO: 147; and
(m) an antibody comprising a heavy chain containing at least the amino acid sequence as set forth in SEQ ID NO: 149, and light chain containing at least the amino acid sequence as set forth in SEQ ID NO: 151.
